[email protected]   +1 (304) 306-0723

Signal Transducer and Activator of Transcription 3 (STAT3) Inhibitors – Pipeline Analytics-2021

$2,500.00$7,500.00

Signal Transducer and Activator of Transcription 3 (STAT3) Inhibitor’s report covers the STAT3 market opportunity providing key Competitive Analysis, 20+ Companies with Pipeline Drug Profiles, Clinical Trials, Other Developments (Collaboration Details, Funding, etc.), Licensing and Agreements, Business Agreement, Business Partner as well as Clinical Partner. Reports covers pipeline product analysis by stage of development, competitive landscape by phases, therapy area, indication and phases. STAT3 inhibitors reports adds a value in terms of providing the description of clinical stage product with respect to their clinical & regulatory timelines as well as monotherapy and combinations.

Clear
SKU: N/A Category:

Description

The targeting of signal transducer and transcription activator 3 (STAT3) inhibitors for different therapeutic areas such as oncology, autoimmune, respiratory, inflammatory, ophthalmology and neurology has generated great interest among companies to develop an emerging class of innovative treatments in these areas. STAT3 inhibitors are known to be a highly desirable target especially within cancer therapy. Based on recent data, STAT3 could be a good therapeutic drug target for developing combinatorial therapy or bispecific antibody therapy.

In this report, Mellalta Meets provided a comprehensive product analysis of the STAT3 pipeline by development phase, therapeutic area, indication and phases. The signal transducer inhibitor and transcription activator 3 (STAT3) pipeline is dominated by preclinical activities which account for 69% of total development, followed by phase II activities which account for 16%, activities phase I and phase III assets which represent 13% and 3% of the pipeline development in STAT3.

STAT-3 Pipeline Products by Stage of Development

The report also provided comprehensive coverage of several types of molecules currently under development such as direct-acting bispecific small molecules, STAT3 RNAi inhibitors or indirect modulators of the STAT3 signaling pathway. At least 35 distinct molecules targeting the STAT3 pathway are under development. Clinical and regulatory timelines of next-stage products such as Sulforaphane (Evgen) and ACT-001 (Accendatech) are the main highlights of the report along with the description of their clinical trial analysis.

Key Highlights of STAT-3 Report

  • The pipeline of STAT3 is dominated by biotech companies headquartered in the United States with the American companies holding the top ten positions. They represent ~50% of all the pipeline STAT3 in clinical stages.
  • Oncology represents ~ 81% of the total STAT3 therapies while the therapy areas namely Autoimmune Diseases , Ophthalmology, Dermatology, Respiratory Diseases, Inflammatory Diseases and Neurology occupy the remaining 11% of the STAT3 trials.

STAT-3 Pipeline Products by Therapy Area

  • The pipeline of STAT3 is dominated by Solid Tumors with the products majorly in Phase I/II and Phase I stages of development. Other Indications studies are Colorectal Adenocarcinoma, Diffuse Intrinsic Pontine Glioma (DIPG), Diffuse large B-cell lymphoma, Head and Neck Cancer, Subarachnoid hemorrhage, Squamous Cell Carcinoma of Head and Neck, Brain tumor, Breast cancer, Hematological cancers etc.
  • There are ~22 products in the Preclinical stage of development, representing 69% of the total share of the developing STAT3 inhibitors landscape.
  • STAT3 pipeline landscape includes 37% of Monotherapy/combination trials, 30% of Monotherapy trials and 33% of Combination Trials.
  • Small Molecule represents 70% of the total STAT3 products while others namely Bispecific Antibody (15%), RNAi Therapies (12%) and TCR Therapy (3%) occupy the remaining 30% of the STAT3
  • To be continued…

Report Coverage:

  • Indication Prioritization: STAT3 Potential based on Indications
  • Business Transactions & Strategies: Key collaborations and deal values
  • STAT3 Pipeline Development: Product Profiles, Clinical Trials & Results
  • STAT3 Competitive Intelligence
  • SWOT Analysis
  • Recent & Upcoming events

Additional information

Price

2-3 User License, Enterprise License, Single User License, Site User License

Table of Contents

  • OVERVIEW
  • KEY TAKEAWAYS
  • The STAT3 Target BACKGROUND
    • STAT3 Signalling Pathway (JAK/STAT3; KRAS/STAT3,; TLR9/STAT3 & Others)
    • STAT3 Target for Cancer Treatment
    • STAT3 Target for Autoimmune Diseases
    • STAT3 Target for COVI19 Complications
    • Current challenges with STAT3 targeting
  • STAT3 PIPELINE ANALYSIS by Phases
    • Pipeline Products by Stage of Development
    • STAT3 Competitive Landscape by Phases
    • Pipeline Products by Company and Phases
    • Pipeline Products by Therapy Area
    • Pipeline Products by Indication and Phases
    • STAT3 Clinical Therapy by Monotherapy & Combinations
    • STAT3 Clinical & Regulatory Timelines
  • STAT3 PIPELINE ANALYSIS by Molecule Type
    • STAT 3 Products by Bispecific Antibodies
    • STAT 3 Products by Monoclonal Antibodies
    • STAT 3 Products by RNA Therapeutics
  • STAT3 LICENSING, ACQUISITION AND COLLABORATION DEALS
    • STAT3 Licensing, Acquisition and Deal values
    • STAT3 Licensing by Transaction type and total amount size by Phases
  • STAT3 Pipeline Landscape
    • Profile Comparisons At–a–glance
    • STAT3 Pipeline Drug Profiles
      • ABM Therapeutics: ABM-2270
        • Product Profile & Description
        • Clinical Trials
        • Collaborations
        • Other Developments 
      • Tianjin Accendatech Technology: ACT-001
        • Product Profile & Description
        • Clinical Trials
        • Collaborations
        • Other Developments 
      • Bio-Path Holdings: BP-1003
        • Product Profile & Description
        • Clinical Trials
        • Collaborations
        • Other Developments 
      • Scopus Biopharma: CpG-STAT3siRNA
        • Product Profile & Description
        • Clinical Trials
        • Collaborations
        • Other Developments 
      • Ionis Pharmaceuticals/AstraZeneca: danvatirsen
        • Product Profile & Description
        • Clinical Trials
        • Collaborations
        • Other Developments 
      • Moleculin: WP1006
        • Product Profile & Description
        • Clinical Trials
        • Collaborations
        • Other Developments 
      • Sumitomo Dainippon Pharma: napabucasin
        • Product Profile & Description
        • Clinical Trials
        • Collaborations
        • Other Developments 
      • To be continued
    • SWOT Analysis
    • Appendix
Name
Email
Phone
Enquiry

Get In Touch

Let's keep the conversation going